Status:

COMPLETED

Renal Transplantation and Raltegravir in HIV-Infected Patients

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Collaborating Sponsors:

Merck Sharp & Dohme LLC

Conditions:

HIV-1 Infection

Chronic Renal Insufficiency

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir...

Detailed Description

Antiretroviral treatment of HIV-1 Infection might interact with immunosuppressive treatments which increase rejection of renal graft incidence. In addition HIV infection may be modified together with...

Eligibility Criteria

Inclusion

  • Registration on the French national renal transplantation waiting list (Biomedicines Agency) for a living or cadaveric donor organ
  • HIV-1-infected patients treated by a three-drug ARV regimen
  • Immuno-virologic criteria at renal transplantation: undetectable viral load (\<50 copies/mL) and CD4 \>200/mm3 for at least three months on stable ARV
  • Age \>18 years and \<70 years
  • Effective contraception for women
  • Written informed consent
  • Patient with social security coverage

Exclusion

  • Permanent:
  • Hepatic cirrhosis
  • Serious psychiatric illness history
  • EBV or HHV8 lymphoproliferation (lymphoma, systemic Kaposi's sarcoma or multifocal Castleman's disease)
  • History of PML
  • HTLV-1 seropositivity
  • Severe pulmonary or cardiovascular disease with poor short-term vital prognosis
  • Patient with AgHBs+
  • History of cryptosporidiosis
  • History of fungal infection with multi resistant fungi not likely to respond to oral antifungal therapy
  • Impossibility or refusal of Raltegravir switch, decision made by doctor or patient
  • Temporary:
  • Recent malignancy (between 2 and 5 years according to type)
  • HPV-related cervical or anal disease: carcinoma in situ, AIN III, CIN III in remission for less than three years
  • Active infection
  • HCV infection (PCR-positive)

Key Trial Info

Start Date :

December 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2015

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT01453192

Start Date

December 1 2011

End Date

November 1 2015

Last Update

July 12 2016

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Hôpital Pellegrin, Service de Nephrologie, Transplantation Rénale, Dialyse

Bordeaux, France, 33076

2

CHU De Caen, Service de Néphrologie Hémodialyse

Caen, France, 14033

3

Hôpital Henri Mondor, Service de Néphrologie Transplantation

Créteil, France, 94010

4

Hôpital Kremlin Bicêtre, Service de Néphrologie

Le Kremlin-Bicêtre, France, 94275